Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA

 

 Buy Article Permissions and Reprints

Abstract

Both an angiotensin II receptor blocker, losartan (CAS 124750-99-8) and a serum urate lowering agent, benzbromarone (CAS 3562-84-3) exert a uricosuric action by inhibiting urate transporter 1 (URAT1). A recent clinical trial indicated that losartan could reduce the level of serum urate in hypertensive patients treated with urate lowering agents, suggesting the different mode of action of losartan from benzbromarone. In the present study, the effect of losartan and benzbromarone on the level of URAT1 mRNA was determined in transfected HEK293 cells. Losartan caused a significant reduction of its mRNA level, whereas it was not affected by benzbromarone. These results indicate that losartan decreases the level of human URAT1 mRNA, which may underlie the uricosuric action of losartan in hypertensive patients treated with serum urate lowering agents.

• Literature

• 1 Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992; 42: 333-5
  PubMedGoogle Scholar
• 2 Edwards RM, Trizna W, Stack EJ, Weinstock J. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transport in rat renal brush-border membranes. J Pharmacol Exp Ther. 1996; 276: 125-9
  PubMedGoogle Scholar
• 3 Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal-Fe R. Effect of eposartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens. 1999; 17: 1033-9
  CrossrefPubMedGoogle Scholar
• 4 Hamada T, Hisatome I, Kinugasa Y, Matsubara K, Shimizu H, Tanaka H et al Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med. 2002; 41: 793-7
  CrossrefPubMedGoogle Scholar
• 5 Buriner M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996; 49: 1787-90
  CrossrefPubMedGoogle Scholar
• 6 Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther. 1997; 280: 839-45
  PubMedGoogle Scholar
• 7 Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH et al Molecular identification of a renal urateanion exchanger that regulates blood urate levels. Nature. 2002; 417: 447-52
  PubMedGoogle Scholar
• 8 Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007; 320: 211-7
  PubMedGoogle Scholar
• 9 Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K et al Uridosuric action of losartan via inhibition of urate transporter (URAT1) in hypertensive patients. Am J Hypertens. 2008; 21: 1157-1162
  CrossrefPubMedGoogle Scholar
• 10 Levinson DJ, Sorensen LB. Renal handling of uric acid in normal and gouty subjects: evidence for a 4-component system. Ann Rheum Dis. 1980; 39: 173-179
  CrossrefPubMedGoogle Scholar
• 11 Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H et al Clinical and molecular analysis of patients with renal hypouricemia in Japan - Influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol. 2004; 15: 164-73
  CrossrefPubMedGoogle Scholar
• 12 Rafey MA, Lipkowitz MS, Leal-Pinto E, Abramson RG. Uric acid transport. Curr Opin Nephrol Hypertens. 2003; 12: 511-6
  CrossrefPubMedGoogle Scholar
• 13 Imaoka T, Kusuhara H, Adachi-Akahane S, Hasegawa M, Morita N, Endou H et al The renal-specific transporter mediates facilitative transport of organic anions at the brush border membrane of mouse renal tubules. J Am Soc Nephrol. 2004; 15: 2012-22
  CrossrefPubMedGoogle Scholar
• 14 Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol. 2005; 9: 195-205
  CrossrefPubMedGoogle Scholar
• 15 Naritomi H, Fujita T, Ito S, Ogihara T, Shimada K, Shima-moto K et al Efficacy and safety of long-term losartan therapy demonstrated by a protective observational study in Japanese patients with hypertension: The Japanese Hypertension Evaluation with Angiotensin II Antagonist Lo-saratan Therapy (J-HEALTH) study. Hypertens Res. 2008; 31: 295-304
  CrossrefPubMedGoogle Scholar